everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...3839404142434445464748...132133»
  • ||||||||||  Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study (GWCC - Hall A1) -  Nov 5, 2021 - Abstract #ASH2021ASH_2211;    
    QPOP predicted frequent sensitivities to Copanlisib- and Venetoclax-based combinations in B-NHL, and Romidepsin-based combinations in T/NK-NHL...Examples include Palbociclib-Everolimus for diffuse large B-cell lymphoma (figure 1) and Romidepsin-copanlisib for extra nodal natural killer T-cell lymphoma...QPOP was however able to identify novel clinically effective combinations in patients refractory to standard therapy. These data provide the basis for a prospective clinical trial evaluating QPOP based therapy in RR-NHL.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies (GWCC - Sidney Marcus Auditorium, Level 4) -  Nov 5, 2021 - Abstract #ASH2021ASH_2116;    
    P1
    Bone marrow aplasia was unexpected and was observed in two subjects who received at least 100 x 10 6 CART37; this was successfully rescued with allogeneic HSCT. Three of four subjects had deep clinical responses in heavily pretreated, refractory disease of diverse lymphoma subtypes.
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
    Retrospective data, Review, Journal:  mTOR inhibitors and risk of ovarian cysts: a systematic review and meta-analysis. (Pubmed Central) -  Nov 4, 2021   
    Ovarian cyst development is a common adverse event during immunosuppression treatment with mTORi. These cysts are benign conditions, but they require pelvic ultrasound follow-up and in some cases hospital admission and surgery.
  • ||||||||||  everolimus / Generic mfg.
    Enrollment closed:  CLEVER-ACS: Controlled Level EVERolimus in Acute Coronary Syndromes (clinicaltrials.gov) -  Nov 3, 2021   
    P1/2,  N=150, Active, not recruiting, 
    These cysts are benign conditions, but they require pelvic ultrasound follow-up and in some cases hospital admission and surgery. Recruiting --> Active, not recruiting
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium (clinicaltrials.gov) -  Nov 1, 2021   
    P2,  N=46, Active, not recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  sirolimus / Generic mfg.
    Clinical, Review, Journal:  Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. (Pubmed Central) -  Oct 31, 2021   
    In 2017, an Italian Working Group of liver transplant experts and hepatologists issued a set of consensus statements along with evidence-based recommendations on the use of everolimus after liver transplantation...The algorithms are divided into two parts, according to the time from transplantation (0-3 months and > 3 months) and are discussed here along with relevant supporting literature, when available. Ultimately, it is hoped that the evidence- and consensus-based algorithms developed within the Italian Working Group, and presented here, contribute to simplify, personalize, and optimize immunosuppression of liver transplantation recipients in clinical practice.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Early Changes in [F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts. (Pubmed Central) -  Oct 30, 2021   
    Reduction in [F]FDG after 2 days correlated with tumor volume changes after 7 days of treatment and confirms the use of [F]FDG PET as an early response biomarker. Treatment response can however be underestimated in schedules containing trastuzumab or everolimus due to temporary increased [F]FDG uptake secondary to negative feedback loop and crosstalk between different pathways.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions. (Pubmed Central) -  Oct 30, 2021   
    For this reason, the mammalian target of rapamycin inhibitors (mTORi) such as sirolimus (SRL) and everolimus (EVE) has been preferred more frequently, as they are associated with fewer complications and longer graft function...Diabetes mellitus (DM) and BK virus nephropathy (BKVN) rates were significantly higher due to switching the regimen from CNI to mTORi. CONCLUSIONS Long-term use of mTORi does not appear to be an immunological problem.
  • ||||||||||  temozolomide / Generic mfg.
    Preclinical, Journal:  3D Primary Cell Culture: A Novel Preclinical Model For Pancreatic Neuroendocrine Tumors (PanNETs). (Pubmed Central) -  Oct 29, 2021   
    Treatment response of islet-like tumoroids (IC50) differs also between patient samples. We believe that the presented human PanNET screening platform is suitable for personalized drug testing in a larger patient cohort and a broader application will help in identifying novel markers predicting treatment response and in refining PanNET therapy.
  • ||||||||||  ceftriaxone / Generic mfg., sirolimus / Generic mfg.
    Journal:  Effects of Broad Spectrum Antibiotics on Measurement of Immunosuppressant Drugs. (Pubmed Central) -  Oct 28, 2021   
    This study demonstrated the potential of antibiotic use affecting immunosuppressant levels. Antibiotic interference, especially in transplant patients, may cause erroneous immunosuppression, increasing the likelihood of rejection.
  • ||||||||||  ondansetron / Generic mfg.
    Clinical, Review, Journal:  Neuroendocrine tumor with diarrhea: not always the usual suspects - a case report of metastatic calcitoninoma with literature review. (Pubmed Central) -  Oct 27, 2021   
    Ondansetron, eventually, seems to be the only therapy, until now, causing a decrease in stool frequency.Functioning pancreatic calcitoninomas are considered to be a rare disease entity with few literature on optimal (nuclear) imaging and treatment. We discuss molecular insights regarding these aspects that can be of great interest to nuclear medicine physicians, pathologists, endocrinologists and gastroenterologists.
  • ||||||||||  Myozyme (alglucosidase alfa) / Sanofi
    Journal:  Enzyme Replacement Therapy may Affect Blood Immunosupressant Monitoring. (Pubmed Central) -  Oct 27, 2021   
    For the measurement of immunosuppressant levels, sampling should be done before the enzyme infusion. Clinicians should question the time of enzyme infusion and sampling when confounding results in immunosuppressant measurement.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors (clinicaltrials.gov) -  Oct 27, 2021   
    P2,  N=32, Recruiting, 
    Everolimus is a safe and effective therapeutic option for renal angiomyolipoma and various manifestations of TSC, which has been reproduced in real life with six years of follow-up. Trial completion date: May 2021 --> Jun 2024 | Trial primary completion date: May 2021 --> Jun 2023
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Clinical, Journal:  Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant. (Pubmed Central) -  Oct 27, 2021   
    The combination of low-dose everolimus and tacrolimus compared with standard-dose tacrolimus safely attenuates LVH in the first year after cardiac transplantation with an observed reduction in CMR-measured fibrosis and an improvement in myocardial strain. This demonstrates that applying available Precision Medicine tools like MTB and real world data sets from patient populations with similar clinical and genomic profiles may provide more options for treatment.
  • ||||||||||  everolimus / Generic mfg., sorafenib / Generic mfg.
    Trial completion date, Metastases:  Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone (clinicaltrials.gov) -  Oct 26, 2021   
    P2,  N=35, Active, not recruiting, 
    This demonstrates that applying available Precision Medicine tools like MTB and real world data sets from patient populations with similar clinical and genomic profiles may provide more options for treatment. Trial completion date: Mar 2021 --> May 2022
  • ||||||||||  docetaxel / Generic mfg.
    Targeting Acetyl-CoA carboxylase in pre-clinical breast cancer models (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_1439;    
    It showed synergy with iniparib and another metabolic inhibitor (TEPP46). Targeting de novo fatty acid synthesis by inhibiting ACC is a promising therapeutic strategy.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Establishment and characterization of two simultaneously developed T-DM1-resistant, ER+/HER2+ XPDX models from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a) (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_1263;    
    Methods : ST4480B and ST4480C were established from a 70-year-old Caucasian female with ER+/HER2+ metastatic breast cancer pretreated with chemotherapy and targeted agents including T-DM1 for nine months followed by capecitabine/trastuzumab/tucatinib combination for one year prior to sample collections...For in vivo studies, both models were evaluated with several chemotherapy and targeted agents alone and in combination including: trastuzumab, pertuzumab, T-DM1, DS-8201a, neratinib, tucatinib, alpelisib, everolimus, and irinotecan...Conclusion : We established two XPDX models representing T-DM1-resistant, ER+/HER2+ breast cancer from both tissue and fluid samples collected simultaneously from the same patient which were found differentially responsive to DS-8201a. These models can be utilized as a valuable tool in better understanding innate resistance to DS-8201a.